PriceTargets.com logo

Avanos Medical - AVNS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$15.75 As of 12/30/2024 01:38 PM ET
▼ -0.17 (-1.07%)

This chart shows the closing price for AVNS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Avanos Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVNS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVNS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Avanos Medical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $15.75.

This chart shows the closing price for AVNS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in Avanos Medical. This rating has held steady since May 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
7/8/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/6/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/4/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/7/2024JMP SecuritiesReiterated RatingMarket Perform
7/25/2023KeyCorpDowngradeOverweight ➝ Sector Weight
5/22/2023CL KingInitiated CoverageBuy$31.00
2/22/2023Morgan StanleyBoost TargetUnderweight$26.00 ➝ $28.00
1/6/2023Morgan StanleyBoost TargetUnderweight$24.00 ➝ $26.00
11/3/2022KeyCorpLower TargetOverweight$38.00 ➝ $34.00
10/11/2022Morgan StanleyLower TargetUnderweight$28.00 ➝ $24.00
8/10/2022KeyCorpLower TargetOverweight$41.00 ➝ $38.00
7/18/2022Stifel NicolausLower Target$37.00 ➝ $28.00
7/15/2022Morgan StanleyLower TargetUnderweight$33.00 ➝ $28.00
2/24/2022KeyCorpLower TargetOverweight$47.00 ➝ $41.00
1/7/2022Morgan StanleyLower TargetUnderweight$37.00 ➝ $36.00
8/4/2021Morgan StanleyLower TargetUnderweight$45.00 ➝ $41.00
8/4/2021KeyCorpLower TargetOverweight$55.00 ➝ $47.00
8/4/2021StephensDowngradeOverweight ➝ Equal Weight$60.00 ➝ $45.00
1/8/2021KeyCorpBoost TargetOverweight$47.00 ➝ $55.00
12/15/2020Morgan StanleyBoost TargetUnderweight$36.00 ➝ $45.00
11/4/2020Morgan StanleyBoost TargetUnderweight$31.00 ➝ $36.00
11/4/2020KeyCorpBoost TargetOverweight$43.00 ➝ $47.00
8/5/2020KeyCorpLower TargetOverweight$45.00 ➝ $43.00
5/7/2020Morgan StanleyBoost TargetUnderweight$29.00 ➝ $31.00
4/27/2020KeyCorpLower TargetOverweight$48.00 ➝ $45.00
4/13/2020BarclaysUpgradeUnderweight ➝ Equal Weight$30.00
4/1/2020Stifel NicolausLower TargetHold$35.00 ➝ $32.00
3/27/2020Morgan StanleyLower TargetSell$32.00 ➝ $29.00
3/23/2020StephensLower TargetOverweight$40.00 ➝ $30.00
2/27/2020BarclaysReiterated RatingSell$32.00
1/28/2020BarclaysReiterated RatingSell$30.00
(Data available from 12/30/2019 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2024
  • 8 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2024
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2024
  • 8 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2024
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2024
  • 3 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2024
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
12/30/2024

Current Sentiment

  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Avanos Medical logo
Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Read More

Today's Range

Now: $15.75
Low: $15.51
High: $15.80

50 Day Range

MA: $18.99
Low: $15.92
High: $22.86

52 Week Range

Now: $15.75
Low: $15.51
High: $25.36

Volume

161,122 shs

Average Volume

252,964 shs

Market Capitalization

$723.82 million

P/E Ratio

46.32

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Avanos Medical?

The following Wall Street analysts have issued stock ratings on Avanos Medical in the last year: JMP Securities, and StockNews.com.
View the latest analyst ratings for AVNS.

What is the current price target for Avanos Medical?

0 Wall Street analysts have set twelve-month price targets for Avanos Medical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Avanos Medical in the next year.
View the latest price targets for AVNS.

What is the current consensus analyst rating for Avanos Medical?

Avanos Medical currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AVNS, but not buy more shares or sell existing shares.
View the latest ratings for AVNS.

What other companies compete with Avanos Medical?

Other companies that are similar to Avanos Medical include iRhythm Technologies, Warby Parker, LivaNova, Enovis and Tandem Diabetes Care. Learn More about companies similar to Avanos Medical.

How do I contact Avanos Medical's investor relations team?

Avanos Medical's physical mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The company's listed phone number is (844) 428-2667 and its investor relations email address is [email protected]. The official website for Avanos Medical is avanos.com. Learn More about contacing Avanos Medical investor relations.